Our Advanced Cell Therapy Center (ACTC) has a GMP cleanroom facility that has been inspected and licensed by the national competent authority (Fimea), and where novel advanced cell therapy products can be produced for clinical use and according to current legislation.
Currently,
allogeneic mesenchymal stromal/stem cells are being produced for the treatment
of refractory graft-versus-host disease in Finnish hematopoietic stem cell
transplant patients (Salmenniemi et al. 2017;
Keto et al. 2018). We also serve the Finnish hospitals with graft
engineering services such as advanced cell selections to enable haploidentical
stem cell transplantations. We are also experienced in isolating keratinocytes
for the experimental treatment of severe burn victims.
Novel
cell therapy products are manufactured at the Advanced Cell Therapy Centre’s
GMP facilities in Helsinki.
Photo on right: Tero Kyllönen/Yle
The
FRCBS is a member of the Eatris research infrastructure ATMP platform and TissueCure Alliance Finland.
